RAPID MICRO BIOSYSTEMS, INC. RPID
We are leading a global transformation toward fully automated microbial quality control ("MQC") within pharmaceutical manufacturing. Our products safeguard the most complex and critical bioprocessing workflows in the industry, enabling faster, safer, and higher capacity drug production. Through our unique expertise at the intersection of microbiology, robotic systems, and advanced vision algorithms, we are setting the foundation for end-to-end quality control automation to enable the future of advanced pharmaceutical manufacturing.
We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics and cell and gene therapies, vaccines, and sterile injectables. Our flagship Growth Direct platform automates and modernizes the antiquated, manual MQC, testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct platform brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that our customers rely on to ensure safe, consistent and timely supply of important healthcare products.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $33.6M | $28.1M | $22.5M | $17.1M | $23.2M | $16.1M | — |
| R&D | $13.6M | $14.6M | $12.8M | $12.9M | $9.8M | $6.5M | — |
| SG&A | $22.8M | $21.9M | $24.9M | $26.8M | $17.9M | $10.0M | — |
| Total operating expenses | $81.0M | $78.0M | $79.1M | $80.4M | $70.5M | $46.6M | — |
| Operating income | -$47.4M | -$49.9M | -$56.6M | -$63.2M | -$47.2M | -$30.5M | — |
| Interest expense | $1.1M | $40.0K | $4.2M | $1.8M | $2.6M | $3.4M | — |
| Pre-tax income | -$47.1M | -$46.9M | -$52.4M | -$61.4M | -$73.4M | -$36.9M | — |
| Income tax | $40.0K | $22.0K | $31.0K | $576.0K | $91.0K | $134.0K | — |
| Net income | -$47.1M | -$46.9M | -$52.5M | -$60.8M | -$73.5M | -$37.1M | — |
| EPS, basic | -1.05 | -1.08 | -1.22 | -1.43 | -3.94 | -126.11 | — |
| EPS, diluted | -1.05 | -1.08 | -1.22 | -1.43 | -3.94 | -126.11 | — |
| Shares, diluted (wtd. avg.) | 44.7M | 43.6M | 43.0M | 42.5M | 19.8M | 358,582 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.0M | $16.9M | $24.6M | $27.3M | $178.7M | $30.2M | $12.6M |
| Short-term investments | $18.3M | $33.8M | $67.8M | $81.6M | $15.1M | $15.0M | — |
| Receivables | $3.1M | $7.5M | $5.5M | $5.4M | $5.0M | $5.0M | — |
| Inventory | $17.6M | $20.2M | $20.0M | $21.2M | $15.7M | $9.0M | — |
| Total current assets | $61.2M | $80.9M | $120.4M | $138.6M | $218.1M | $62.1M | — |
| Property, plant and equipment | $9.0M | $11.2M | $12.8M | $13.8M | $11.3M | $7.1M | — |
| Total assets | $74.9M | $98.2M | $143.5M | $190.7M | $241.2M | $70.0M | — |
| Accounts payable | $4.1M | $2.5M | $2.0M | $5.4M | $3.9M | $4.5M | — |
| Total current liabilities | $18.5M | $17.6M | $19.0M | $19.1M | $18.2M | $15.5M | — |
| Long-term debt | $18.9M | $0 | — | $0 | $0 | $24.8M | — |
| Total liabilities | $41.6M | $22.8M | $25.5M | $26.5M | $20.2M | $45.2M | — |
| Retained earnings | -$522.4M | -$475.3M | -$428.4M | -$375.9M | -$315.1M | -$241.6M | — |
| Total equity | $33.2M | $75.4M | $118.0M | $164.2M | $221.0M | -$127.0M | -$82.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.1M | -$44.2M | -$45.1M | -$58.5M | -$55.0M | -$31.0M | — |
| Depreciation and amortisation | $3.3M | $3.4M | $3.1M | $2.8M | $1.5M | $1.5M | — |
| Stock-based compensation | $4.0M | $3.9M | $4.8M | $4.0M | $1.8M | $533.0K | — |
| Capital expenditure | $850.0K | $1.4M | $1.8M | $6.7M | $3.2M | $690.0K | — |
| Investing cash flow | $14.3M | $36.7M | $42.2M | -$93.5M | -$13.3M | -$15.7M | — |
| Financing cash flow | $19.8M | $203.0K | $149.0K | $693.0K | $216.7M | $64.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001380106-26-000034.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $16.1M | $23.2M | $17.1M | $22.5M | $28.1M | $33.6M |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$37.1M | -$73.5M | -$60.8M | -$52.5M | -$46.9M | -$47.1M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Results announced Item 2.02
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $48.79B | 37.9x | 6.7% |
| WAT | WATERS CORP /DE/ | $44.57B | 42.2x | 7.0% |
| ILMN | ILLUMINA, INC. | $40.68B | 49.4x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $33.47B | 39.7x | 4.0% |
| RVTY | REVVITY, INC. | $17.72B | 76.7x | 3.7% |
| AVTR | Avantor, Inc. | $11.80B | — | -3.4% |
| BIO | BIO-RAD LABORATORIES, INC. | $9.89B | 13.3x | 0.7% |
| TXG | 10x Genomics, Inc. | $9.30B | — | 5.2% |